ATR and neoplasm: Several studies have suggested that tumor cells with high levels of DNA replication stress (overexpressing replication stress-inducing oncogenes such as RAS, CCNE1 or MYC), genetic deficiencies in TP53 or ATM, or defects in homologous recombination, will likely be more vulnerable to ATR inhibitors [17–20].